Related Experiment Video
Updated: Apr 14, 2026
MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
Published on: August 11, 2015
Early MRI activity predicts treatment nonresponse with intramuscular interferon beta-1a in clinically isolated
R P Kinkel1, J H Simon2, P O'Connor3
1Department of Neurosciences, University of California San Diego, 9500 Gilman Dr, MC 0662, La Jolla, CA 92093, USA.
Objective:
Determine whether MRI activity 6 months after treatment initiation in the Controlled High-Risk Subjects Avonex® Multiple Sclerosis Prevention Study (CHAMPS) predicted progression to clinically definite multiple sclerosis (CDMS) over the subsequent 30 months in intramuscular interferon beta-1a (IM IFNβ-1a)-treated patients vs placebo-treated patients.
Methods:
CHAMPS patients were randomized to once-weekly IM IFNβ-1a 30 μg or placebo for up to 36 months. MRI was performed every 6 months until CDMS confirmation. Patient groups were defined based on new T2 and/or Gd+ lesions at 6 months.
Results:
Thirteen IM IFNβ-1a patients (6.7%) and 24 placebo patients (12.6%) developed CDMS prior to month 6 and did not undergo the 6-month MRI. At 6 months, 29.7% of IM IFNβ-1a-treated patients vs 40.9% of placebo-treated patients were defined as having high MRI activity levels (≥2 new T2 and/or ≥2 Gd+ lesions). In this subgroup, estimated cumulative probabilities of CDMS were similar between groups (HR=0.88 [0.44-1.77], p=0.7227). A significant treatment response was seen for patients with <2 new T2 and <2 Gd+ lesions at 6 months (HR=0.39 [0.19-0.82], p=0.0120).
Conclusion:
MRI scans 6 months after IM IFNβ-1a initiation in CIS patients predict early treatment non-response. Standardized scanning and monitoring may facilitate early disease management.
Insights
Magnetic Resonance Imaging (MRI) activity six months after starting treatment with intramuscular interferon beta-1a (IM IFNβ-1a) can predict treatment response in patients with clinically isolated syndrome (CIS). Early identification of non-responders can guide disease management.
Area of Science:
- Neurology
- Immunology
- Radiology
Background:
- Multiple Sclerosis (MS) is a chronic neurological disease.
- Early intervention with disease-modifying therapies (DMTs) like interferon beta-1a (IFNβ-1a) aims to prevent disease progression.
- Predictive biomarkers are crucial for optimizing treatment strategies.
Purpose of the Study:
- To evaluate if Magnetic Resonance Imaging (MRI) activity at 6 months predicts conversion to clinically definite multiple sclerosis (CDMS).
- To compare the predictive value of early MRI activity between patients treated with intramuscular interferon beta-1a (IM IFNβ-1a) and placebo.
- To assess the utility of early MRI findings for guiding MS treatment decisions.
Main Methods:
- Analysis of data from the Controlled High-Risk Subjects Avonex® Multiple Sclerosis Prevention Study (CHAMPS).
- Patients received either once-weekly IM IFNβ-1a 30 μg or placebo.
- MRI scans were conducted every 6 months; patient groups were stratified by MRI lesion activity at 6 months.
Main Results:
- High MRI activity (≥2 new T2 and/or ≥2 Gd+ lesions) at 6 months showed similar CDMS progression rates between IM IFNβ-1a and placebo groups (HR=0.88).
- Patients with low MRI activity (<2 new T2 and <2 Gd+ lesions) at 6 months demonstrated a significant treatment response to IM IFNβ-1a (HR=0.39, p=0.0120).
- Early MRI findings distinguished responders from non-responders to IM IFNβ-1a.
Conclusions:
- Six-month MRI scans after initiating IM IFNβ-1a can predict early treatment non-response in patients with clinically isolated syndrome (CIS).
- Standardized MRI monitoring may enable timely adjustments to MS treatment strategies.
- This approach could improve long-term management of MS.
